Biovian, a CDMO specializing in biopharmaceuticals, is investing over €50 million to expand its manufacturing facility in Turku, Finland to meet growing demand for innovative biologics and gene therapies.

The new 69,000 square foot facility will house cutting-edge equipment and advanced technologies to support the development, manufacturing, and testing of advanced therapy medicinal products (ATMPs), such as adenoviral and AAV (adeno-associated viral) therapies. It will also feature dedicated Class A to D cleanroom areas for bulk drug substances as well as final drug product manufacture.

The expansion project is expected to be completed in December 2024, with the new facility fully operational by 2025. The investment is expected to create 100 job opportunities in the region.

The additional space complements Biovian’s existing manufacturing facilities in the area and will enable Biovian to undertake larger-scale viral vector as well as microbial protein projects and concurrent manufacturing campaigns by increasing overall production capacity and flexibility.

Biovian specializes in the production of biologics, gene therapies, and vaccines, working with GMP E. coli recombinant proteins and viral vectors such as AAV and adenovirus. The investment will enable Biovian to offer end-to-end services, from early-stage development to commercial-scale manufacturing, serving the diverse needs of its biopharmaceutical customers.

“The new manufacturing facility will not only strengthen Biovian’s position as a key player in the CDMO sector, but also contribute to the growth of the biopharmaceutical industry in Finland and most of all provide vital therapies to patients suffering from today’s untreatable diseases,” said Antti Nieminen, CEO of Biovian. “Biovian aims to facilitate swift drug development and delivery, reducing time-to-market for its customers, all while creating an enjoyable experience. The new manufacturing facility will increase viral vector capacity, but it will also increase our capacity and flexibility in microbial protein. When the new site is up and running, our existing capacity will be transformed to new microbial protein suites. Thus, both microbial and viral vector customers will benefit from this expansion.”